Sakuchio’s choice of biological agents following failed treatment of silver crumbs – Xue

Silver crumbs is a common chronic inflammatory skin disease, and Sakuchio is a widely used biological agent that works by inhibiting white cellulin – 17A. However, the use of Sukuchio monotherapy by some patients may be ineffective. When Sakuchio has failed, other biological agents need to be carefully selected.Consideration of white cell media – 12/23 inhibitorsUssnu resistance: It regulates the immune system and inhibits inflammation by blocking the p40 subunits that are common to white cellulin-12 and white cellulin-23. For some patients who use the Sakuchiyo to fight effectively, usnu resistance may be an effective alternative. It is given in a relatively convenient manner and is usually maintained at a certain time interval after the initial dose. For example, some persons with moderate-heavy scavenging silver crumbs are still active in the aftermath of the Sukucyo monotherapy, which has been converted into usnu monotherapy, and have gradually improved the symptoms of red spots and crumbs in their skin. Their long-term safety is also significant, and the adverse effects are mostly light and reversible, such as in the injection sector.Guisecchiu is one-sided: it works primarily in the p19 sub-unit of white cellin – 23, which precisely inhibits access to specific inflammations. For those who have a poor response to Sukuchiyo’s monotherapy, especially for the types of silver crumbs driven by the inflammation mainly by white cytin-23, Guisechio’s monotherapy may be more effective. Among some of the hard-to-do patients with silver crumbs, Guisecchio ‘ s single resistance can effectively reduce the area and severity of silver crumbs (PASI) and improve the quality of life of patients.II. Cause of death – Alpha (TNF – alpha) inhibitorAdawood is a monoclonic antibodies that combines the TNF-α and disrupts its biological activity. In the treatment of silver crumbs, when Sakuchiyo is less effective, Adamu alone can play an inflammatory role. It has been applied clinically for many years, and for people with arthropodic silver crumbs, the Adam single resistance not only improves skin disease but also mitigates joint symptoms. However, the use of the Adawood monologue also requires attention to its possible adverse effects, such as increased risk of infection, including tuberculosis, so that relevant screening is required prior to use.Inflisi is a human rat-embedded monoclon antibodies that inhibit interactions with receptors by combining with TNF-α. In a number of cases of silver crumbs against Sakuchio alone, Inflisi alone can induce a reduction. It usually uses intravenous infusion, which works relatively quickly. However, because of its structure, which contains rat-source components, there may be some immunogenic reactions, such as the infusion response, requiring close observation of the patient during the infusion.Exploration of new biological agentsDual-specific antibodies: These can be targeted at two different target points at the same time, for example, for white cell media – 17 and another inflammation-related molecule. They provide new treatment thinking for those who have failed to treat single target biological agents (e.g., Sakuchio). Although the application in the area of silver crumb treatment is still in its initial stages, it shows its potential effectiveness and good tolerance.Small Molecular Biological Agents: Small Molecular Biological Agents have advantages such as oral delivery, compared to traditional Large Molecular Biological Agents. They play an anti-inflammatory role by inhibiting the transmission of signals within cells. The successful development and application of small molecular biological agents will provide easier treatment options for patients who have failed in the Sakuchio monotherapy.When the single treatment of silver crumbs failed, doctors needed to take into account the specific conditions of the patient, his or her treatment response, his or her complications and financial factors, and to select the biological agents most suitable for the patient in order to achieve the best treatment. At the same time, patients need to follow closely the changes in their symptoms and possible adverse reactions in the use of new biological agents and to communicate with doctors in a timely manner.